Nadelmann J, Frishman W H
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Drugs. 1990 Jun;39(6):862-76. doi: 10.2165/00003495-199039060-00005.
beta-Blockers are effective in reducing the blood pressure of many patients with systemic hypertension. They differ in terms of the presence or absence of intrinsic sympathomimetic activity, membrane-stabilising activity, beta 1-selectivity, alpha-blocking properties, and relative potency and duration of action. All beta-blockers appear to have blood pressure lowering effects. The choice of which beta-blocker to use in an individual patient is determined by the pharmacodynamic and pharmacokinetic differences between the drugs in conjunction with the patient's other medical condition(s). This review discusses the practical use of beta-blockers and provides rational suggestions for which drug(s) to use in selected patient groups (Black, elderly, postinfarction, diabetes, renal disease, obstructive lung disease, elevated lipid levels, coexisting angina, and left ventricular hypertrophy).
β受体阻滞剂对降低许多系统性高血压患者的血压有效。它们在有无内在拟交感活性、膜稳定活性、β1选择性、α阻断特性以及相对效价和作用持续时间方面存在差异。所有β受体阻滞剂似乎都有降压作用。在个体患者中选择使用哪种β受体阻滞剂,取决于药物之间的药效学和药代动力学差异以及患者的其他病情。本综述讨论了β受体阻滞剂的实际应用,并针对特定患者群体(黑人、老年人、心肌梗死后、糖尿病、肾病、阻塞性肺病、血脂升高、并存心绞痛和左心室肥厚)使用哪种药物提供了合理建议。